The 5-HT2A serotoninergic receptor is expressed in the MCF-7 human breast cancer cell line and reveals a mitogenic effect of serotonin - PubMed

Affiliations

• PMID: 16580628
• DOI: 10.1016/j.bbrc.2006.03.080

The 5-HT2A serotoninergic receptor is expressed in the MCF-7 human breast cancer cell line and reveals a mitogenic effect of serotonin

Brigitte Sonier et al. Biochem Biophys Res Commun. 2006.

Abstract

Serotonin (5-hydroxytryptamine, 5-HT) has been described as a mitogen in a variety of cell types and carcinomas. It exerts its mitogenic effect by interacting with a wide range of 5-HT receptor types. Certain studies suggest that some selective serotonin re-uptake inhibitors promote breast cancer in animals and humans. This study attempts to clarify the role of serotonin in promoting the growth of neoplastic mammary cells. Expression of the 5-HT(2A) serotoninergic receptor subtype in MCF-7 cells was determined by RT-PCR, Western blotting, and immunofluorescence analysis. The mitogenic effect of 5-HT on MCF-7 cells was determined by means of the MTT proliferation assay. We have demonstrated that the 5-HT(2A) receptor subtype is fully expressed in the MCF-7 human breast cancer cell line, in terms of encoding mRNA and receptor protein. Automated sequencing has confirmed that the 5-HT(2A) receptor present in this cell line is identical to the 5-HT(2A) receptor found in human platelets and in human cerebral cortex. Furthermore, this receptor was found by immunofluorescence to be on the plasma membrane. MTT proliferation assays revealed that 5-HT and DOI, a selective 5-HT(2A) receptor subtype agonist, stimulated MCF-7 cell. These results indicate that 5-HT plays a mitogenic role in neoplastic mammary cells. Our data also indicate that 5-HT exerts this positive growth effect on MCF-7 cells through, in part, the 5-HT(2A) receptor subtype, which is fully expressed in this cell line.

Similar articles

• Expression of the 5-HT2A serotoninergic receptor in human placenta and choriocarcinoma cells: mitogenic implications of serotonin.

  Sonier B, Lavigne C, Arseneault M, Ouellette R, Vaillancourt C. Sonier B, et al. Placenta. 2005 Jul;26(6):484-90. doi: 10.1016/j.placenta.2004.08.003. Placenta. 2005. PMID: 15950062

• Functional expression of 5-HT2A receptor in osteoblastic MC3T3-E1 cells.

  Hirai T, Kaneshige K, Kurosaki T, Nishio H. Hirai T, et al. Biochem Biophys Res Commun. 2010 May 28;396(2):278-82. doi: 10.1016/j.bbrc.2010.04.078. Epub 2010 Apr 23. Biochem Biophys Res Commun. 2010. PMID: 20399747

• The 5-HT 2A serotonin receptor enhances cell viability, affects cell cycle progression and activates MEK-ERK1/2 and JAK2-STAT3 signalling pathways in human choriocarcinoma cell lines.

  Oufkir T, Arseneault M, Sanderson JT, Vaillancourt C. Oufkir T, et al. Placenta. 2010 May;31(5):439-47. doi: 10.1016/j.placenta.2010.02.019. Epub 2010 Mar 25. Placenta. 2010. PMID: 20338635

• Serotonin induces melanogenesis via serotonin receptor 2A.

  Lee HJ, Park MK, Kim SY, Park Choo HY, Lee AY, Lee CH. Lee HJ, et al. Br J Dermatol. 2011 Dec;165(6):1344-8. doi: 10.1111/j.1365-2133.2011.10490.x. Epub 2011 Oct 17. Br J Dermatol. 2011. PMID: 21711335

• Is the Exposome Involved in Brain Disorders through the Serotoninergic System?

  Sarrouilhe D, Defamie N, Mesnil M. Sarrouilhe D, et al. Biomedicines. 2021 Sep 29;9(10):1351. doi: 10.3390/biomedicines9101351. Biomedicines. 2021. PMID: 34680468 Free PMC article. Review.

Cited by

• Biogenic amines serotonin and dopamine regulate cholangiocyte hyperplastic and neoplastic growth.

  Frampton GA, Li H, Ramirez J, Mohamad A, Demorrow S. Frampton GA, et al. World J Gastrointest Pathophysiol. 2010 Jun 15;1(2):63-8. doi: 10.4291/wjgp.v1.i2.63. World J Gastrointest Pathophysiol. 2010. PMID: 21607143 Free PMC article.

• Combination therapy in combating cancer.

  Bayat Mokhtari R, Homayouni TS, Baluch N, Morgatskaya E, Kumar S, Das B, Yeger H. Bayat Mokhtari R, et al. Oncotarget. 2017 Jun 6;8(23):38022-38043. doi: 10.18632/oncotarget.16723. Oncotarget. 2017. PMID: 28410237 Free PMC article. Review.

• Serotonin signalling in cancer: Emerging mechanisms and therapeutic opportunities.

  Chen L, Huang S, Wu X, He W, Song M. Chen L, et al. Clin Transl Med. 2024 Jul;14(7):e1750. doi: 10.1002/ctm2.1750. Clin Transl Med. 2024. PMID: 38943041 Free PMC article. Review.

• Breast cancer and neurotransmitters: emerging insights on mechanisms and therapeutic directions.

  Jayachandran P, Battaglin F, Strelez C, Lenz A, Algaze S, Soni S, Lo JH, Yang Y, Millstein J, Zhang W, Shih JC, Lu J, Mumenthaler SM, Spicer D, Neman J, Roussos Torres ET, Lenz HJ. Jayachandran P, et al. Oncogene. 2023 Feb;42(9):627-637. doi: 10.1038/s41388-022-02584-4. Epub 2023 Jan 18. Oncogene. 2023. PMID: 36650218 Free PMC article. Review.

• Ineffective erythropoiesis with reduced red blood cell survival in serotonin-deficient mice.

  Amireault P, Hatia S, Bayard E, Bernex F, Collet C, Callebert J, Launay JM, Hermine O, Schneider E, Mallet J, Dy M, Côté F. Amireault P, et al. Proc Natl Acad Sci U S A. 2011 Aug 9;108(32):13141-6. doi: 10.1073/pnas.1103964108. Epub 2011 Jul 25. Proc Natl Acad Sci U S A. 2011. PMID: 21788492 Free PMC article.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Elsevier Science

• Other Literature Sources

  • The Lens - Patent Citations Database

• Medical

  • MedlinePlus Health Information